NASDAQ · TWST

Twist Bioscience Corporation

$86.54 -$3.73 (-4.13%) 1D Pre-market

Key Metrics

$5.62B
Market cap
P/E · TTM
Revenue · TTM
−$81.28M
Net income
EPS · TTM $-1.32
Dividend yield
Free cash flow −$95.04M
Beta · 1Y 2.43
EBITDA · TTM −$55.86M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Apr 14
    The stock moved +14.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 14
  • Feb 2
    The stock moved +14.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 2

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$5.62B
Enterprise value
Shares outstanding62.3M
52-wk range$23.30 – $105.47
Avg volume · 20D1.1M
Net cash
Book value / share$7.41
IndustryBiological Products, (No Diagnostic Substances)
ExchangeNASDAQ
About Twist Bioscience Corporation
IPO dateOct 31, 2018
Employees979

Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC -17.5% · -28.7%

Financial Health

Current ratio2.70
Quick ratio2.42
Debt / equity
Debt / EBITDA
Net cash
Working capital$203.46M

Cash Flow · TTM

Operating CF −$55.59M
Capex −$39.45M
Free cash flow −$95.04M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings